Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Neuropathic Pain -Products under Investigation by Universities/Institutes, H2 2016

Friday, January 6, 2017 7:22
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

Report Highlights:

This report Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 6, 27, 29, 1, 119, 21 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 1 molecules, respectively.

 

Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis

For more information about this report at http://www.reportsweb.com/neuropathic-pain-pipeline-review-h2-2016

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)

Request a sample copy at http://www.reportsweb.com/inquiry&RW0001513493/sample

Reasons to buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Companies profiles

2-BBB Medicines BV

AbbVie Inc

Acadia Pharmaceuticals Inc

Achelios Therapeutics Inc

Adynxx Inc

Aevi Genomic Medicine Inc

Affectis Pharmaceuticals AG

Amura Holdings Ltd

AnaBios Corp

Anavex Life Sciences Corp

AngioChem Inc

APT Therapeutics Inc

Aquilus Pharmaceuticals Inc

Araim Pharmaceuticals Inc

Ask for Discount at http://www.reportsweb.com/inquiry&RW0001513493/discount

Few Points from List of Tables

Neuropathic Pain – Pipeline by 2-BBB Medicines BV, H2 2016 70

Neuropathic Pain – Pipeline by AbbVie Inc, H2 2016 71

Neuropathic Pain – Pipeline by Acadia Pharmaceuticals Inc, H2 2016 72

Neuropathic Pain – Pipeline by Achelios Therapeutics Inc, H2 2016 73

Neuropathic Pain – Pipeline by Adynxx Inc, H2 2016 74

Neuropathic Pain – Pipeline by Aevi Genomic Medicine Inc, H2 2016 75

Neuropathic Pain – Pipeline by Affectis Pharmaceuticals AG, H2 2016 76

Neuropathic Pain – Pipeline by Amura Holdings Ltd, H2 2016 77

Neuropathic Pain – Pipeline by AnaBios Corp, H2 2016 78

Neuropathic Pain – Pipeline by Anavex Life Sciences Corp, H2 2016 79

Neuropathic Pain – Pipeline by AngioChem Inc, H2 2016 80

Neuropathic Pain – Pipeline by APT Therapeutics Inc, H2 2016 81

Neuropathic Pain – Pipeline by Aquilus Pharmaceuticals Inc, H2 2016 82

Neuropathic Pain – Pipeline by Araim Pharmaceuticals Inc, H2 2016 83

Neuropathic Pain – Pipeline by Arena Pharmaceuticals Inc, H2 2016 84

Contact Us:                 
Call: +1-646-491-9876
Email: sales@reportsweb.com

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.